Reported about 1 month ago
A recent survey by KFF reveals that the majority of US Medicaid programs do not cover popular weight-loss drugs from Novo Nordisk and Eli Lilly, mainly due to cost concerns. Only 12 out of 50 states include these medications for obesity treatment, and while some states are considering changes, hefty monthly costs, starting around $1,000, hinder broader access. The survey highlights increasing Medicaid expenses alongside declining enrollment, as many states prepare to tighten budgets amid rising healthcare costs.
Source: YAHOO